Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Journal article

Peer reviewed

Naval Daver, Takayuki Ikezoe, Justin Watts, Naoko Hosono, Yoshiaki Ogawa, Yasushi Miyazaki, Harry P. Erba, John Affinito, Emily Brooks, Ken Eguchi, …

Blood, Vol.140(Supplement 1), pp.3371-3372

2022-11-15

Metrics

1 Record Views

Title: Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)
Creators: Naval Daver - The University of Texas MD Anderson Cancer Center
Takayuki Ikezoe - Fukushima Medical University Hospital
Justin Watts - University of Miami
Naoko Hosono - University of Fukui
Yoshiaki Ogawa - Tokai University
Yasushi Miyazaki - Nagasaki University
Harry P. Erba - Duke University
John Affinito - Sumitomo Pharma Oncology, Cambridge, MA
Emily Brooks - Sumitomo Pharma Oncology, Cambridge, MA
Ken Eguchi - Sumitomo Dainippon Pharma
Hongliang Cai - Sumitomo Pharma Oncology, Cambridge, MA
Bo Xu - Sumitomo Pharma Oncology, Cambridge, MA
Jay Stoudemire - Sumitomo Pharma Oncology, Cambridge, MA
Matthew Hitron - Sumitomo Pharma Oncology, Cambridge, MA
Akinobu Watanabe - Sumitomo Pharma Oncology, Cambridge, MA
Philip Komarnitsky - Sumitomo Pharma Oncology, Cambridge, MA
Junichiro Yuda - National Cancer Center Hospital East
Publication Details: Blood, Vol.140(Supplement 1), pp.3371-3372
Publisher: Elsevier Inc; AMSTERDAM
Number of pages: 2
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991032860814902976